Answers are grounded in this paper and cite their sources.
In this trial involving patients with HER2-low metastatic breast cancer, trastuzumab deruxtecan resulted in significantly longer progression-free and overall survival than the physician's choice of chemotherapy. (Funded by Daiichi Sankyo and AstraZeneca; DESTINY-Breast04 ClinicalTrials.gov number, NCT03734029.).
No takes yet. Share an insight, caveat, or question.
Modi et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: